PHYSIOLOGICAL LEVELS OF ESTRADIOL STIMULATE PLASMA HIGH-DENSITY LIPOPROTEIN(2) CHOLESTEROL LEVELS IN NORMAL MEN

被引:82
作者
BAGATELL, CJ
KNOPP, RH
RIVIER, JE
BREMNER, WJ
机构
[1] UNIV WASHINGTON, SCH MED, CTR RES REPROD, DEPT MED & POPULAT, SEATTLE, WA 98108 USA
[2] UNIV WASHINGTON, NW LIPID RES CTR, SEATTLE, WA 98104 USA
[3] SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA
关键词
D O I
10.1210/jc.78.4.855
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Premenopausal women have a lower risk of coronary artery disease than men or postmenopausal women; estrogens are thought to contribute to this lower risk. Administration of exogenous estrogen to postmenopausal women increases plasma high density lipoprotein (HDL) cholesterol and may reduce mortality from coronary disease in users. Although many investigations have examined the roles of estrogen in the regulation of lipoproteins in women, little attention has been directed to estrogen regulation of lipids in men. We designed a paradigm to study the role of physiological levels of estradiol (E(2)) on plasma lipoproteins in healthy men. We used a GnRH antagonist, Nal-Glu, to suppress endogenous steroid hormones in healthy men. We then administered testosterone (T) enanthate (100 mg, im, weekly) to restore T levels to the baseline range, and we administered an aromatase inhibitor, testolactone (Teslac), to prevent the normal conversion of T to E(2), thereby producing a selective estrogen deficiency state in normal young men. As controls, we administered Nal-Glu and T along with placebo Teslac to a separate group of men; a third group of men received all placebo medications. We found that in men who received Nal-Glu plus T plus Teslac, E(2) levels were profoundly suppressed during treatment, whereas T levels remained in the baseline range. Plasma HDL cholesterol, particularly, the HDL(2) fraction, decreased significantly in response to the low serum E(2) level. Plasma apoprotein-AI levels also decreased significantly. Plasma LDL and triglyceride levels did not change. All hormone and lipoprotein parameters returned to baseline within 4 weeks after treatment ended. In men who received Nal-Glu plus T, plasma HDL and apoprotein-AI decreased, but these decreases did not achieve statistical significance. Only a small decrease in HDL(2) cholesterol was seen in these men. There were no hormonal or lipid changes in the placebo group. We conclude that in men, physiological levels of E(2) are important in maintaining plasma levels of HDL cholesterol, especially the HDL(2) fraction. These observations suggest that estrogen, in the amount normally produced in men, may offer some degree of protection against cardiovascular disease in males, as they do in women.
引用
收藏
页码:855 / 861
页数:7
相关论文
共 42 条
  • [1] EFFECT OF ESTROGEN ON POST-HEPARIN LIPOLYTIC-ACTIVITY - SELECTIVE DECLINE IN HEPATIC TRIGLYCERIDE LIPASE
    APPLEBAUM, DM
    GOLDBERG, AP
    PYKALISTO, OJ
    BRUNZELL, JD
    HAZZARD, WR
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1977, 59 (04) : 601 - 608
  • [2] Bachorik P S, 1986, Methods Enzymol, V129, P78
  • [3] A COMPARISON OF THE SUPPRESSIVE EFFECTS OF TESTOSTERONE AND A POTENT NEW GONADOTROPIN-RELEASING HORMONE ANTAGONIST ON GONADOTROPIN AND INHIBIN LEVELS IN NORMAL MEN
    BAGATELL, CJ
    MCLACHLAN, RI
    DEKRETSER, DM
    BURGER, HG
    VALE, WW
    RIVIER, JE
    BREMNER, WJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 69 (01) : 43 - 48
  • [4] PHYSIOLOGICAL TESTOSTERONE LEVELS IN NORMAL MEN SUPPRESS HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS
    BAGATELL, CJ
    KNOPP, RH
    VALE, WW
    RIVIER, JE
    BREMNER, WJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 116 (12) : 967 - 973
  • [5] BLACKARD CE, 1970, CANCER, V26, P249, DOI 10.1002/1097-0142(197008)26:2<249::AID-CNCR2820260202>3.0.CO
  • [6] 2-7
  • [7] DAY-TO-DAY VARIABILITY OF SERUM-CHOLESTEROL, TRIGLYCERIDE, AND HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS - IMPACT ON THE ASSESSMENT OF RISK ACCORDING TO THE NATIONAL CHOLESTEROL EDUCATION-PROGRAM GUIDELINES
    BOOKSTEIN, L
    GIDDING, SS
    DONOVAN, M
    SMITH, FA
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (08) : 1653 - 1657
  • [8] SERUM-LIPID CHANGES AFTER ESTROGEN THERAPY IN PROSTATIC-CARCINOMA
    BULUSU, NV
    LEWIS, SB
    DAS, S
    CLAYTON, WE
    [J]. UROLOGY, 1982, 20 (02) : 147 - 150
  • [9] CARDIOVASCULAR MORTALITY AND NONCONTRACEPTIVE USE OF ESTROGEN IN WOMEN - RESULTS FROM THE LIPID RESEARCH CLINICS PROGRAM FOLLOW-UP-STUDY
    BUSH, TL
    BARRETTCONNOR, E
    COWAN, LD
    CRIQUI, MH
    WALLACE, RB
    SUCHINDRAN, CM
    TYROLER, HA
    RIFKIND, BM
    [J]. CIRCULATION, 1987, 75 (06) : 1102 - 1109
  • [10] INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY
    CASTELLI, WP
    GARRISON, RJ
    WILSON, PWF
    ABBOTT, RD
    KALOUSDIAN, S
    KANNEL, WB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20): : 2835 - 2838